Page 3 - Implicit Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The laboratory-created monoclonal antibody, called IC14, binds to a human protein, CD14, that is found on the surface of immune cells circulating in the blood and airway fluid and that also circulates as a stand-alone protein. CD14 helps immune cells recognize pathogens and injured or dying cells, alerting the immune system to danger and prompting it to respond.

Vanderbilt universityUnited statesFoster cityMarkm wurfelThomasr martinAnthonys fauciEmily hendersonNational institute of allergyNational institutes of healthVanderbilt university in nashvilleGilead sciences incDivision of pulmonaryTolerance networkMedicine at university of washingtonImplicit bioscience ltdNational institute